Health
Russia’s COVID-19 vaccine shows over 91% efficacy in phase 3 trial: Lancet study – The Tribune India
Findings based on analysis of data from nearly 20,000 participants; Sputnik V is a two-part vaccine that includes two adenovirus vectors
Moscow, February 2
Russia’s Sputnik V vaccine against COVID-19 has shown 91.6 per cent efficacy in the phase 3 trial without any serious side effects, according to an interim analysis of data published in The Lancet journal on Tuesday.
The findings are based on analysis of data from nearly 20,000 participants – three-quarters of whom received the two-dose regimen of the adenovirus-based vaccine, Gam-COVID-Vac, and one quarter received a placebo.
Serious adverse events or those requiring hospital…
-
General23 hours agoNRLW Sunday: Brisbane Broncos hammer Newcastle Knights, Cronulla Sharks move to third on ladder
-
Noosa News13 hours agoForum responds to urgent homelessness issues in Nambour
-
General12 hours agoEnergy provider ENGIE to ‘correct’ electricity bills for thousands of South Australian customers
-
Noosa News12 hours agoQueensland weather forecast sees sunny weather for last week of winter